Clinical Cancer Research AACR Conference on Cancer Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 81-89, January 1, 2007. doi: 10.1158/1078-0432.CCR-06-1560
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rojo, F.
Right arrow Articles by Cajal, S. R. y
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rojo, F.
Right arrow Articles by Cajal, S. R. y

Human Cancer Biology

4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis

Federico Rojo1, Laura Najera1, José Lirola1, José Jiménez1, Marta Guzmán3, M. Dolors Sabadell2, Jose Baselga3 and Santiago Ramon y Cajal1

Authors' Affiliations: Departments of 1 Pathology, 2 Gynecology, and 3 Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Requests for reprints: Santiago Ramon y Cajal, Department of Pathology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron, 119-129 08035 Barcelona, Spain. Phone: 34-93-274-6809, ext. 6824; Fax: 34-93-274-6818; E-mail: sramon{at}vhebron.net.

Purpose: Cell signaling pathways include a complex myriad of interconnected factors from the membrane to the nucleus, such as erbB family receptors and the phosphoinositide-3-kinase/Akt/mTOR and Ras-Raf-ERK cascades, which drive proliferative signals, promote survival, and regulate protein synthesis.

Experimental Design: To find pivotal factors in these pathways, which provide prognostic information in malignancies, we studied 103 human breast tumors with an immunohistochemical profile, including total and phosphorylated (p) proteins: human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor, extracellular signal-regulated kinase 1/2, Akt, 4E-binding protein 1 (4EBP1), eukaryotic initiation factor 4E, phosphorylated ribosomal protein S6 kinase 1, phosphorylated ribosomal protein S6, and Ki67. Western blot and reverse lysate protein arrays were also done in a subset of tumors.

Results: Significantly, activation of the phosphoinositide-3-kinase/Akt/mTOR cascade was detected in a high proportion of tumors (41.9%). Tumors with HER2 overexpression showed higher p-Akt as compared with negative tumors (P < 0.001). Levels of p-Akt correlated with the downstream molecules, p-4EBP1 (P = 0.001) and p-p70S6K (P = 0.05). Although 81.5% of tumors expressed p-4EBP1, in 16.3% of these tumors, concomitant activation of the upstream factors was not detected. Interestingly, p-4EBP1 was mainly expressed in poorly differentiated tumors (P < 0.001) and correlated with tumor size (P < 0.001), presence of lymph node metastasis (P = 0.002), and locoregional recurrences (P = 0.002). Coexpression of p-4EBP1 and p-eIF4G correlated with a high tumor proliferation rate (P = 0.012).

Conclusion: In this study, p-4EBP1 was the main factor in signaling pathways that associate with prognosis and grade of malignancy in breast tumors. Moreover, p-4EBP1 was detected in both HER2-positive and HER2-negative tumors. This factor seems to be a channeling point at which different upstream oncogenic alterations converge and transmit their proliferative signal, modulating protein translation.




This article has been cited by other articles:


Home page
JCOHome page
A. Jimeno, M. A. Rudek, P. Kulesza, W. W. Ma, J. Wheelhouse, A. Howard, Y. Khan, M. Zhao, H. Jacene, W. A. Messersmith, et al.
Pharmacodynamic-Guided Modified Continuous Reassessment Method-Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors
J. Clin. Oncol., September 1, 2008; 26(25): 4172 - 4179.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson, K. Hazell, E. Martinelli, S. R. y Cajal, S. Jones, L. Vidal, et al.
Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
J. Clin. Oncol., April 1, 2008; 26(10): 1603 - 1610.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Angelo, M. Anita, A. Amalia, and T. Stefania
Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?
Clin. Cancer Res., October 15, 2007; 13(20): 5988 - 5990.
[Full Text] [PDF]


Home page
Cancer Res.Home page
G. Armengol, F. Rojo, J. Castellvi, C. Iglesias, M. Cuatrecasas, B. Pons, J. Baselga, and S. Ramon y Cajal
4E-Binding Protein 1: A Key Molecular "Funnel Factor" in Human Cancer with Clinical Implications
Cancer Res., August 15, 2007; 67(16): 7551 - 7555.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.